Drug intelligence / Profile preview

OCX-410

Development stage: Preclinical
Lead developer: Ocean Biomedical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

OCX-410 is a bispecific antibody developed by Ocean Biomedical through its subsidiary Ocean Chitorx, Inc. It was exclusively sublicensed from Elkurt, Inc., with the original technology licensed from Brown University. The drug is designed to target both FRG and PD-1, and is being developed for use in oncology. Ocean Biomedical plans to advance this candidate from preclinical stages towards clinical trials.

Targets

CHI3L1 (Chitinase-3-like protein 1)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on OCX-410.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCX-410.

Explore the full profile